Progress in the treatment of immunoglobulin A nephropathy with budesonide extended-release capsules

VernacularTitle:布地奈德缓释胶囊治疗免疫球蛋白A肾病的研究进展
Author: Yang LIU ^{1
,

2} ; Panpan JIN ; Bo QIU ; Huizhen WU
Author Information

1. 河北医科大学研究生学院,石家庄 050017,河北
2. 河北省人民医院药学部,河北省临床药学重点实验室,石家庄 050051,河北
Keywords: budesonide extended-release cap-sules; immunoglobulin A nephropathy; TARGIT technology; clinical research
From: Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(9):1062-1069
CountryChina
Language:Chinese
Abstract: Immunoglobulin A nephropathy is a common autoimmune nephropathy.A growing body of research suggests that immunoglobulin A nephropathy may be associated with dysfunction of the mucosal immune system.Immunoglobulin A nephropathy is characterized by thylakoid deposi-tion of galactose-deficient IgA1 immune complex-es,which are thought to originate from mucosal B-cells,which are abundantly present in the distal ile-um,which is rich in Pyle's collecting lymph nodes.A novel targeted release formulation of budesonide has been shown to deliver the drug to the distal ileum with the aim of minimizing adverse events in patients with immunoglobulin A nephrop-athy.This article reviews the mechanism of action,dosage form characteristics,clinical studies,drug interactions and adverse events,and limitations of budesonide extended-release capsules.